Evidence map›Paper›PMID 36146844›Full record

ArticleViruses2022

SARS-CoV-2 Seroprevalence Study in Pediatric Patients and Health Care Workers Using Multiplex Antibody Immunoassays.

Esther Prados de la Torre, Ignacio Obando, Marta Vidal, Beatriz de Felipe, Ruth Aguilar, Luis Izquierdo, Carlo Carolis, Peter Olbrich, Ana Capilla-Miranda, Pau Serra and 5 more

Abstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Esther Prados de la TorreDepartamento de Bioquímica y Biología Molecular, Campus de Excelencia Internacional CeiA3, Universidad de Córdoba, 14071 Córdoba, Spain.ORCID 0000-0002-3991-4964
Ignacio ObandoUnidad de Pediatría, Sección de Infectología, Reumatología e Inmunología Pediátrica, Hospital Infantil Virgen del Rocío, Instituto de Biomedicina de Sevilla, RITIP, 41012 Sevilla, Spain.
Marta VidalISGlobal, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.
Beatriz de FelipeUnidad de Pediatría, Sección de Infectología, Reumatología e Inmunología Pediátrica, Hospital Infantil Virgen del Rocío, Instituto de Biomedicina de Sevilla, RITIP, 41012 Sevilla, Spain.
Ruth AguilarISGlobal, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.
Luis IzquierdoISGlobal, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-3704-9874
Carlo CarolisBiomolecular Screening and Protein Technologies Unit, Centre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, 08003 Barcelona, Spain.ORCID 0000-0003-4240-1139
Peter OlbrichUnidad de Pediatría, Sección de Infectología, Reumatología e Inmunología Pediátrica, Hospital Infantil Virgen del Rocío, Instituto de Biomedicina de Sevilla, RITIP, 41012 Sevilla, Spain.
Ana Capilla-MirandaUnidad de Pediatría, Sección de Infectología, Reumatología e Inmunología Pediátrica, Hospital Infantil Virgen del Rocío, Instituto de Biomedicina de Sevilla, RITIP, 41012 Sevilla, Spain.ORCID 0000-0001-8318-8202
Pau SerraInstitut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Pere SantamariaInstitut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), 08036 Barcelona, Spain.
Pilar Blanco-LoboUnidad de Pediatría, Sección de Infectología, Reumatología e Inmunología Pediátrica, Hospital Infantil Virgen del Rocío, Instituto de Biomedicina de Sevilla, RITIP, 41012 Sevilla, Spain.ORCID 0000-0003-1893-8198
Gemma MoncunillISGlobal, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0001-5105-9836
Manuel J Rodríguez-OrtegaDepartamento de Bioquímica y Biología Molecular, Campus de Excelencia Internacional CeiA3, Universidad de Córdoba, 14071 Córdoba, Spain.ORCID 0000-0002-8744-7045
Carlota DobañoISGlobal, Hospital Clínic-Universitat de Barcelona, 08036 Barcelona, Spain.ORCID 0000-0002-6751-4060

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 infection has become a global health problem specially exacerbated with the continuous appearance of new variants. Healthcare workers (HCW) have been one of the most affected sectors. Children have also been affected, and although infection generally presents as a mild disease, some have developed the Pediatric Inflammatory Multisystem Syndrome Temporally Associated with SARS-CoV-2 (PIMS-TS). We recruited 190 adults (HCW and cohabitants, April to June 2020) and 57 children (April 2020 to September 2021), of whom 12 developed PIMS-TS, in a hospital-based study in Spain. Using an in-house Luminex assay previously validated, antibody levels were measured against different spike and nucleocapsid SARS-CoV-2 proteins, including the receptor-binding domain (RBD) of the Alpha, Beta, Gamma, and Delta variants of concern (VoC). Seropositivity rates obtained from children and adults, respectively, were: 49.1% and 11% for IgG, 45.6% and 5.8% for IgA, and 35.1% and 7.3% for IgM. Higher antibody levels were detected in children who developed PIMS-TS compared to those who did not. Using the COVID-19 IgM/IgA ELISA (Vircell, S.L.) kit, widely implemented in Spanish hospitals, a high number of false positives and lower seroprevalences compared with the Luminex estimates were found, indicating a significantly lower specificity and sensitivity. Comparison of antibody levels against RBD-Wuhan versus RBD-VoCs indicated that the strongest positive correlations for all three isotypes were with RBD-Alpha, while the lowest correlations were with RBD-Delta for IgG, RBD-Gamma for IgM, and RBD-Beta for IgA. This study highlights the differences in antibody levels between groups with different demographic and clinical characteristics, as well as reporting the IgG, IgM, and IgA response to RBD VoC circulating at the study period.

Indexed as

COVID-19AdultAntibodies, ViralChildHealth PersonnelHumansImmunoassayImmunoglobulin AImmunoglobulin GImmunoglobulin MPandemicsSARS-CoV-2Seroepidemiologic StudiesSpike Glycoprotein, CoronavirusSystemic Inflammatory Response SyndromeAntibodies, ViralImmunoglobulin AImmunoglobulin GImmunoglobulin MSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2antibodyantigenchildrencohortCOVID-19healthcare workersPIMS-TSSARS-CoV-2seropositivity

Identifiers

PMID36146844
PMCPMC9502584

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.